Details for New Drug Application (NDA): 219757
✉ Email this page to a colleague
NDA 219757 describes VOSTALLY, which is a drug marketed by Rosemont Pharms and is included in one NDA. There is one patent protecting this drug. Additional details are available on the VOSTALLY profile page.
The generic ingredient in VOSTALLY is ramipril. There are nineteen drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the ramipril profile page.
The generic ingredient in VOSTALLY is ramipril. There are nineteen drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the ramipril profile page.
Summary for 219757
| Tradename: | VOSTALLY |
| Applicant: | Rosemont Pharms |
| Ingredient: | ramipril |
| Patents: | 1 |
Medical Subject Heading (MeSH) Categories for 219757
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;ORAL | Strength | 1MG/ML | ||||
| Approval Date: | Jul 23, 2025 | TE: | RLD: | Yes | |||||
| Patent: | 12,343,338 | Patent Expiration: | Aug 16, 2039 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | VOSTALLY IS INDICATED FOR THE TREATMENT OF HYPERTENSION, TO LOWER BLOOD PRESSURE | ||||||||
Complete Access Available with Subscription
